Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought ... GLP-1 agonists include semaglutide - the basis of weight ...

Video Back Videos home Signature collection Essentials collection Artificial Intelligence ...

Video Back Videos home Signature collection Essentials collection Artificial Intelligence ...

Using real-world data from over 300,000 cases, scientists uncovered a significant link between semaglutide and reported vision problems—raising new concerns about the safety profile of this ...

However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively).

Most common gastrointestinal issues seen were nausea/vomiting, abdominal pain, and diarrhea. HealthDay News — The rate of emergency department visits for adverse events among patients dispensed ...

Semaglutide, the medication better known as Ozempic, reduces the symptoms of a condition that can lead to lower limb amputations in people with diabetes, according to a new study that reinforces ...

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...

The researchers found that based on 551 cases, there were an estimated 24,499 emergency department visits attributed to semaglutide adverse events in 2022 through 2023 (mean patient age, 50.9 ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date. (HealthDay News) — For patients with diabetes, semaglutide use is ...